Incyte Co. (NASDAQ:INCY) had its price target upped by Morgan Stanley from $130.00 to $150.00 in a research note published on Tuesday. They currently have an overweight rating on the biopharmaceutical company’s stock.

Other equities analysts have also issued reports about the company. Goldman Sachs Group Inc boosted their target price on Incyte from $116.00 to $149.00 and gave the stock a buy rating in a research report on Friday, January 27th. Vetr upgraded Incyte from a buy rating to a strong-buy rating and set a $133.50 price objective for the company in a research report on Monday, January 30th. JMP Securities reiterated an outperform rating and issued a $130.00 price objective on shares of Incyte in a research report on Wednesday, January 18th. Zacks Investment Research upgraded Incyte from a strong sell rating to a hold rating in a research report on Wednesday, March 22nd. Finally, Barclays PLC boosted their price objective on Incyte from $105.00 to $135.00 and gave the company a buy rating in a research report on Thursday, January 19th. Three investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average target price of $139.40.

Incyte (NASDAQ:INCY) traded down 0.11% during midday trading on Tuesday, reaching $122.98. 996,303 shares of the company’s stock traded hands. Incyte has a 52 week low of $68.03 and a 52 week high of $153.15. The company’s 50-day moving average price is $138.77 and its 200 day moving average price is $114.39. The stock has a market capitalization of $23.29 billion, a price-to-earnings ratio of 227.74 and a beta of 0.78.



Incyte (NASDAQ:INCY) last announced its quarterly earnings data on Tuesday, February 14th. The biopharmaceutical company reported $0.05 EPS for the quarter, missing the Zacks’ consensus estimate of $0.14 by $0.09. The firm earned $326 million during the quarter, compared to analyst estimates of $324.90 million. Incyte had a return on equity of 50.38% and a net margin of 14.71%. Incyte’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.29 earnings per share. On average, equities research analysts expect that Incyte will post ($0.08) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Incyte Co. (INCY) Price Target Raised to $150.00” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/04/21/incyte-co-incy-price-target-raised-to-150-00.html.

In other news, EVP Steven H. Stein sold 32,000 shares of the company’s stock in a transaction that occurred on Friday, April 7th. The stock was sold at an average price of $137.88, for a total transaction of $4,412,160.00. Following the sale, the executive vice president now owns 41,648 shares in the company, valued at approximately $5,742,426.24. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jean Jacques Bienaime acquired 1,000 shares of the company’s stock in a transaction dated Friday, April 7th. The shares were bought at an average price of $139.48 per share, for a total transaction of $139,480.00. Following the purchase, the director now owns 2,177 shares in the company, valued at $303,647.96. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 127,571 shares of company stock worth $18,145,772. Company insiders own 13.70% of the company’s stock.

Large investors have recently made changes to their positions in the company. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of Incyte by 1.7% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,322 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 22 shares in the last quarter. Seven Bridges Advisors LLC boosted its stake in shares of Incyte by 27.1% in the third quarter. Seven Bridges Advisors LLC now owns 1,867 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 398 shares in the last quarter. Douglass Winthrop Advisors LLC bought a new stake in shares of Incyte during the first quarter worth about $201,000. Pinnacle Associates Ltd. bought a new stake in shares of Incyte during the fourth quarter worth about $212,000. Finally, IFM Investors Pty Ltd bought a new stake in shares of Incyte during the fourth quarter worth about $214,000. Institutional investors own 92.62% of the company’s stock.

About Incyte

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

5 Day Chart for NASDAQ:INCY

Receive News & Stock Ratings for Incyte Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Co. and related stocks with our FREE daily email newsletter.